{
    "clinical_study": {
        "@rank": "10169", 
        "brief_summary": {
            "textblock": "131I-metaiodobenzylguanidine (131I-MIBG) is a norepinephrine analog that concentrates in\n      adrenergic tissue and therefore holds promise for cell-specific treatment of neuroblastoma.\n      This is a dual institution, Phase II study of 131I-MIBG administered at the previously\n      defined maximum practical dose of 18 mCi/kg to children with relapsed or refractory\n      neuroblastoma."
        }, 
        "brief_title": "CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study", 
        "condition": "Neuroblastoma", 
        "condition_browse": {
            "mesh_term": "Neuroblastoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria: Refractory neuroblastoma with original diagnosis based on tumor\n        histopathology or elevated urine VMA with typical tumor cells in the bone marrow."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "firstreceived_date": "March 29, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00013806", 
            "org_study_id": "NCRR-M01RR00240-1748"
        }, 
        "intervention": {
            "intervention_name": "131I-MIBG", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "3-Iodobenzylguanidine"
        }, 
        "keyword": "Relapsed and refractory neuroblastoma", 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19104"
                }, 
                "name": "Children's Hospital of Philadelphia"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00013806"
        }, 
        "source": "National Center for Research Resources (NCRR)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2003"
    }, 
    "geocoordinates": {
        "Children's Hospital of Philadelphia": "39.952 -75.164"
    }
}